Uji Efek Penurunan Glukosa Darah Dapagliflozin Monoterapi Dan Kombinasi Dengan Glucose Lowering Agent Lainnya

Almas Amalul Fasha(1*), Ikhwan Yuda Kusuma(2), Galih Samodra(3)

(1) Program Studi Farmasi, Universitas Harapan Bangsa Purwokerto
(2) Program Studi Farmasi, Universitas Harapan Bangsa Purwokerto
(3) Program Studi Farmasi, Universitas Harapan Bangsa Purwokerto
(*) Corresponding Author

Abstract

The success of DM therapy with antidiabetic drug monotherapy is about 25-50% effectiveness, therefore combination therapy is needed. Inhibitor sodium glucose co-transporter 2 (SGLT-2) is a new anti-diabetic drug intended for personal therapy of patients with type 2 diabetes. SGLT2 inhibitors work by inhibiting glucose reabsorption in the proximal tubule so that glucose will be excreted with urine. SGLT-2 besides being used as monotherapy can also be combined with other DM drugs.  This study aimed to determine the effectiveness of dapagliflozin monotherapy compared to metformin, saxagliptin and glimepiride in alloxan-induced Balb-c strain mice. This research was conducted experimentally on alloxan-induced hyperglycemic mice and the treatment was given for 7 days. The treatment groups were: I. normal, II. alloxan, III. dapagliflozin (D) and the dapagliflozin combination group with: IV. Metformin (DM), V. saxagliptin (DS), VI. Glimepiride (DG), VII. saxagliptin + metformin (DSM). Analysis of the decrease in blood sugar compared between groups on the 7th day after administration. The analysis was carried out using ANOVA test with a 95% confidence level. The results of this study indicate that all treatments with antidiabetic drugs alone or in combination given for 7 days can control blood sugar levels to <120 mg/dL. The combination of dapaglyfozine (DM, DS, DSM) showed a significant difference with groups D and DG (p<0.05). The combination of dapagliflozin with Metformin, Saxagliptin and Meformin+Sazagliptin showed a good effectiveness in lowering blood sugar levels compared to other combinations and alone.

 

Keywords

Diabetes mellitus, Metformin, Dapagliflozin, Saxagliptin, Glimepiride

Full Text:

PDF

References

Akrom, Harjanti P.D. and Armansyah T., 2014, Efek Hipoglikemik Ektrak Etanol Umbi Ketela Rambat (Ipomoea batatas P) ada Mencit Swiss Yang Diinduksi Aloksan, Pharmaciana, 4 (1), 65.

Dipiro J,, Yee G., Posey L., Haines S., Nolin T. and Ellingrod V., 2020, Pharmacotherapy: A Pathophysiologic Approach. 11th Edition, 11th ed., New york.

Djuwarno E.N. and Abdulkadir W., 2019, Penurunan Kadar Glukosa Mencit, Journal Syifa Sciences and Clinical Research, 1, 8–13.

Fulcher G., Matthews D.R., Perkovic V., de Zeeuw D., Mahaffey K.W., Weiss R., Rosenstock J., Capuano G., Desai M., Shaw W., Vercruysse F., Meininger G. and Neal B., 2015, Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial, Diabetes Therapy, 6 (3), 289–302.

He L. and Wondisford F.E., 2015, Metformin action: Concentrations matter, Cell Metabolism, 21 (2), 159–162. Terdapat di: http://dx.doi.org/10.1016/j.cmet.2015.01.003.

IDF, 2019, IDF Diabetes Atlas Ninth edition 2019, Terdapat di: http://www.idf.org/about-diabetes/facts-figures.

Ighodaro O.M., Adeosun A.M. and Oluseyi Adeboye Akinloye, 2017, Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies, Medicina (Lithuania), 53 (6), 365–374.

Ikawati, Z, 2015, Farmakologi molekuler, Gadjah Mada University Press, Yogyakarta.

Kalra S., Kesavadev J., Chadha M. and Vijaya Kumar G., 2018, Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus, Indian Journal of Endocrinology and Metabolism, 22 (6), 827–836.

Kristin E., 2016, Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus, Journal of thee Medical Sciences, 48 (02), 119–130.

Li M., Li X., Zhang H. and Lu Y., 2018, Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment, Frontiers in Physiology, 9 (July), 1–7.

Milder T.Y., Stocker S.L., Abdel Shaheed C., McGrath-Cadell L., Samocha-Bonet D., Greenfield J.R. and Day R.O., 2019, Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis, Journal of Clinical Medicine, 8 (1), 45.

Muller T.D., Finan B., Bloom S.R., D’Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F., Holst J.J., Langhans W., Meier J.J., Nauck M.A., Perez-Tilve D., Pocai A., et al., 2019, Glucagon-like peptide 1 (GLP-1), Molecular Metabolism, 30, 72–130.

Terdapat di: https://doi.org/10.1016/j.molmet.2019.09.010.

Paresh D. and Chaudhuri A., 2017, Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician, International Journal of Clinical Practice, 71 (5), 1–14.

Perkeni, 2015, Konsesus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe2 Di Indonesia 2015, Pengurus Besar Perkumpulan Endokrinologi Indonesia, Jakarta. Terdapat di: https://www.google.com/url?sa=t&source=web&rct=j&url=https://pbperkeni.or.id/wp-content/uploads/2019/01/4.-Konsensus-Pengelolaan-dan-Pencegahan-Diabetes-melitus-tipe-2-di-Indonesia-PERKENI2015.pdf&ved=2ahUKEwjy8KOs8cfoAhXCb30KHQb1Ck0QFjADegQIBhAB&usg=AOv.

Riskesdas, 2018, Hasil Utama Riset Kesehata Dasar (RISKESDAS), Journal of Physics A: Mathematical and Theoretical, 44 (8), 1–200. Terdapat di: http://arxiv.org/abs/1011.1669%0Ahttp://dx.doi.org/10.1088/1751-8113/44/8/085201%0Ahttp://stacks.iop.org/1751-8121/44/i=8/a=085201?key=crossref.abc74c979a75846b3de48a5587bf708f.

Santoso S., 2014, Panduan lengkap SPSS Versi 20 Edisi Revisi, PT. Alex Media Komputindo, Jakarta.

Sukiatno L., Kusuma I.Y. and Samodra G., 2021, Cardioprotective and Renoprotective Effects of the Use of SGLT2 Inhibitors in Diabetes Mellitus Patients, , 34 Advances in Health Sciences Research, 121–127.

DOI: 10.23917/pharmacon.v0i0.15839

Article Metrics

Abstract view(s): 328 time(s)
PDF: 831 time(s)

Refbacks

  • There are currently no refbacks.